$112.17
2.39%
Nasdaq, Oct 16, 04:00 pm EDT. Closed.
ISIN
US6536561086
Symbol
NICE

NICE Ltd Sponsored ADR Stock price

$112.17
+6.74 6.39% 1M
+7.13 6.78% 6M
-0.88 0.77% YTD
-16.18 12.60% 1Y
-53.84 32.43% 3Y
-163.94 59.38% 5Y
+45.41 68.01% 10Y
+80.23 251.17% 20Y
Nasdaq, Closing price Fri, Oct 16 2026
-2.75 2.39%
ISIN
US6536561086
Symbol
NICE
Industry

AI Insights on NICE Ltd Sponsored ADR Insights AI Insights on NICE Ltd Sponsored ADR

How does the company make money?
Who are the company’s main competitors?
What are the key opportunities and risks?
How is the company managed?

Is NICE Ltd Sponsored ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,109 stocks worldwide.

Key metrics

Basic
Market capitalization
$6.5b
Enterprise Value
$6.2b
Net debt
positive
Cash
$354.7m
Shares outstanding
58.4m
Valuation
P/E
16.0
P/S | estimate
2.1 | 2.0
EV/Sales | estimate
2.0 | 1.9
EV/FCF | ex SBC
11.0 | 15.9
P/B
1.7
Dividends
DPS
$0.00
Yield 1Y | 5Y
0.0% | 0.0%
Growth 1Y | 5Y
- | -
Payout 1Y | 3Y
0.0% | 0.0%
Increased
0 Years
Financials
Revenue | estimate
$3.1b | $3.2b
EBITDA
$815.9m
EBIT
$580.6m
Net Income
$425.5m
Free Cash Flow | ex SBC
$561.7m | $387.9m
Growth
Revenue | estimate
8.1% | 10.2%
EBITDA
2.4%
EBIT
-4.4%
Net Income
-20.2%
Free Cash Flow
-14.9%
Margin
Gross
65.1%
EBITDA
26.6%
EBIT
18.9%
Net
13.9%
Free Cash Flow | ex SBC
18.3% | 12.6%
Financial Health
Equity Ratio
75.9%
Return on Equity
15.8%
ROCE
14.5%
ROIC
9.3%
Debt/Equity
0.0
Share-Based Compensation & Dilution
SBC | % of Revenue
$173.8m | 5.7%
SBC as % of FCF
30.9%
SBC Growth 1Y
-12.4%
Share Count Growth 1Y
-7.2%
Shareholder Yield
7.2%
More
EPS
$7.2
FCF per Share
$9.6
Short interest
2.4%
Employees
-
Rev per Employee
-

NICE Ltd Sponsored ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

15 Analysts have issued a NICE Ltd Sponsored ADR forecast:

10x Buy
67%
5x Hold
33%

Analyst Opinions

15 Analysts have issued a NICE Ltd Sponsored ADR forecast:

Buy
67%
Hold
33%

NICE Ltd Sponsored ADR Events

Past Events
AUG
5
Q2 2026 Earnings Call
2 months ago
JUN
9
Analyst/Investor Day - NICE Ltd.
4 months ago
MAY
6
Q1 2026 Earnings Call
5 months ago
MAR
3
Morgan Stanley Technology
8 months ago
FEB
19
Q4 2025 Earnings Call
8 months ago
DEC
10
53rd Annual Nasdaq Investor Conference
10 months ago
DEC
2
UBS Global Technology and AI Conference 2025
11 months ago
NOV
17
Analyst/Investor Day - NICE Ltd.
11 months ago
NOV
13
Q3 2025 Earnings Call
11 months ago

Financial data from NICE Ltd Sponsored ADR

Jun '26
+/-
%
3,069 3,069
8% 8%
100%
- Direct Costs 1,071 1,071
14% 14%
35%
1,999 1,999
5% 5%
65%
- Selling and Administrative Expenses 1,036 1,036
11% 11%
34%
- Research and Development Expense 382 382
5% 5%
12%
816 816
2% 2%
27%
- Depreciation and Amortization 235 235
24% 24%
8%
EBIT (Operating Income) EBIT 581 581
4% 4%
19%
Net Profit 425 425
20% 20%
14%

In millions USD.

Don't miss a Thing! We will send you all news about NICE Ltd Sponsored ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

NICE Ltd Sponsored ADR Stock News

Neutral
GlobeNewsWire
●
11 days ago
Company Recognized for Connecting Public Sector Organizations With AI-Powered Customer Service Solutions Company Recognized for Connecting Public Sector Organizations With AI-Powered Customer Service Solutions
Neutral
Business Wire
●
15 days ago
HOBOKEN, N.J.--(BUSINESS WIRE)--NiCE (Nasdaq: NICE) today announced it has been positioned in the Leaders category in the IDC MarketScape: Worldwide Agentic Contact Center–as-a-Service Platforms 2026 Vendor Assessment (doc #US54117326, August 2026). We believe NiCE's position underscores the strength of its unified CX AI platform, bringing CXone and NiCE Cognigy together to orchestrate every in...
Neutral
Business Wire
●
16 days ago
CAMBRIDGE, England--(BUSINESS WIRE)--FOR UK HEALTHCARE/TRADE MEDIA ONLY Sobi® UK today announced that the National Institute for Health and Care Excellence (NICE) has issued final draft guidance which recommends Tryngolza® (olezarsen) as an option to treat genetically confirmed familial chylomicronaemia syndrome (FCS) in adults in England and Wales, only if response to diet and conventional tri...
More NICE Ltd Sponsored ADR News

Company Profile

NICE Ltd. engages in the provision of enterprise software solutions and services. It operates through the following segments: Customer Interactions Solutions, Security Solutions, and Financial Crime and Compliance Solutions. The Customer Interactions Solutions segment provides suites such as compliance and risk, workforce optimization, operational efficiency, customer experience, and sales and retention. The Security Solutions segment offers suites including incident debriefing and investigation; public safety emergency response optimization; video surveillance and analytics; situation management; and intelligence and law enforcement. The Financial Crime and Compliance Solutions segment includes for enterprise risk management, anti-money laundering, fraud prevention, and brokerage compliance services. The company was founded on September 28, 1986 and is headquartered in Raanana, Israel.

Head office Israel
CEO Mr. Russell
Founded 1986
Website www.nice.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today